Company / Net Income
Tvardi Therapeutics, Inc. Net Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$85.5M
FY2024
5-year range
-$106.4M / $8.4M
FY2020-FY2024
Trend
+3.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income has fluctuated over the past 10 years, ranging from -$106M in FY2021 to $8M in FY2022.
Based on SEC 10-K filings.
-$85M in FY2024.
Declined from $8M to -$85M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, net income increased 3.4% year-over-year.
- Peak net income was recorded in FY2022.
- Lowest net income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$85.5M | +3.4% |
| FY2023 | -$88.4M | -1151.6% |
| FY2022 | $8.4M | +107.9% |
| FY2021 | -$106.4M | -43.7% |
| FY2020 | -$74.0M | -27.3% |
| FY2019 | -$58.1M | -1.5% |
| FY2018 | -$57.3M | -132.0% |
| FY2017 | -$24.7M | -39.1% |
| FY2016 | -$17.7M | -347.8% |
| FY2015 | -$4.0M | +36.8% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026